iTeos Therapeutics, Inc.

NASDAQ:ITOS

16.7 (USD) • At close September 13, 2024
Bedrijfsnaam iTeos Therapeutics, Inc.
Symbool ITOS
Munteenheid USD
Prijs 16.7
Beurswaarde 609,914,060
Dividendpercentage 0%
52-weken bereik 8.2 - 18.75
Industrie Biotechnology
Sector Healthcare
CEO Dr. Michel Detheux Ph.D.
Website https://www.iteostherapeutics.com

An error occurred while fetching data.

Over iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with

Vergelijkbare Aandelen

ZimVie Inc. logo

ZimVie Inc.

ZIMV

16.45 USD

InnovAge Holding Corp. logo

InnovAge Holding Corp.

INNV

5.99 USD

Atai Life Sciences N.V. logo

Atai Life Sciences N.V.

ATAI

1.3 USD

Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

AVIR

3.87 USD

Nkarta, Inc. logo

Nkarta, Inc.

NKTX

5.71 USD

Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

5.8 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

28.78 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)